A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Kodiak Sciences Inc
- Study ID
- NCT06996080
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Macular Edema Secondary to Inflammation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KSI-101 — DRUGIntravitreal injection
- Sham Comparator — OTHERSham injections
Study Details
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Key Dates
- Start date
- Jul 16, 2025
- Status verified
- May 2026
- Primary completion
- Feb 28, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 300 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: KSI-101 5 mgIntravitreal injection of KSI-101 5 mg once every 4 weeks for 6 monthly doses followed by individualized dosing
- Experimental: KSI-101 10 mgIntravitreal injection of KSI-101 10 mg once every 4 weeks for 6 monthly doses followed by individualized dosing
- Sham Comparator: ShamSham injection once every 4 weeks for 6 monthly doses followed by individualized sham dosing
Primary Outcome Measure
Mean change in BCVA [ Time Frame: Week 24 ]
Central Contacts
- Kodiak Sciences Inc(650) 281-0850
Locations (55)
Find similar trials in Phoenix, AZ
Related Studies
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKPHASE3 · Recruiting · Kodiak Sciences Inc · Phoenix, Arizona